ALIVUS (Alivus Life Sciences Limited, formerly Glenmark Life Sciences) - Breakout
Breakout observed in daily timeframe of Alivus, the company has a very good chart pattern and is in a good uptrend and recently broke out with good volumes. The breakout has also been retested and sustained. There could be a good upside in this stock. The company also has good fundamentals as written below.
Fundamentals.
MCap 14,299Cr
Stock P/E 32.4
Industry P/E 31.6
ROCE 28.1%
ROE 21.1%
NPM 20.6%
PEG Ratio 1.69
Debt 16Cr
Reserves 2,514Cr
EPS 36.05
Promoter holding 75%
API contribution 9MFY24
Chronic : 69%
Acute : 31%
Key Therapeutic areas contribution 9MFY24
Diabetes : 4%
CVS : 41%
CNS : 17%
Pain Management : 6%
Others : 32%
Business segments
The company has two key segments - Generics and Complex APIs (92% of FY23 revenue) and Contract Development and Manufacturing Operations (CDMO) (8% of FY23 revenue)
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在
使用條款閱讀更多資訊。